Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECOVID: Sirolimus in COVID-19 Pneumonia
NCT04948203Phase 3Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Jul 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sirolimus in COVID-19 pneumonia (3 arms), sponsored by University of Chicago. Primary endpoint: Prevalence of Pulmonary Fibrosis as evidenced by CT scan at 12 weeks. Started Jul 2021; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04948203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948203.